Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GAIA BioMedicine

Request full access

Developing a new platform to generate nk-like cells that can effectively eliminate solid tumors without the need for genetic modification

Fukuoka, JapanFounded 2015Biotech & Life Sciences

About GAIA BioMedicine

GAIA BioMedicine, established in 2015 as a spin-off from Kyushu University, is a clinical-stage biopharmaceutical company headquartered in Fukuoka, Japan. The company was founded by Professor Yoshikazu Yonemitsu of the Graduate School of Kyushu University, leveraging his research to address intractable diseases. GAIA BioMedicine operates in the immuno-oncology market, focusing on the development of cell therapies to combat solid tumors.

The core of GAIA BioMedicine's work is its proprietary technology platform for developing "off-the-shelf" allogeneic NK-like cell therapies. The lead candidate, GAIA-102, consists of natural killer (NK)-like cells derived from healthy donors. A key feature of this platform is its ability to produce these cells without the need for genetic modification, which is often a complex and costly part of other cell therapy manufacturing processes. The GAIA-102 cells are designed to exhibit strong anti-tumor cytotoxic potency. The company is advancing several cell therapy programs based on this platform and currently has three ongoing clinical trials targeting various solid cancers, including non-small cell lung cancer (NSCLC) and peritoneal dissemination from gastric or pancreatic cancer.

The company's business model is centered on the research, development, and eventual commercialization of these cell therapies. Revenue generation is anticipated through partnerships, licensing agreements, and the future sale of its therapeutic products. GAIA BioMedicine has successfully raised capital through multiple funding rounds to support its clinical trials and platform development. The company has secured investments from a mix of venture capital firms and strategic corporate partners, including SBI Investment, Hisamitsu Pharmaceutical, Osaka University Venture Capital, and JIC Venture Growth Investments. A notable collaboration was announced in February 2023 with TreeFrog Therapeutics, a French biotech company, to utilize their C-Stem™ technology for the large-scale expansion of GAIA's donor-derived NK-like cells, addressing the mass-production needs for treating highly prevalent cancers.

Source: Dealroom company data

GAIA BioMedicine in the Fukuoka ecosystem

Live from Dealroom

The GAIA BioMedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • AMED

Series A5 investors entered at this stage

  • Osaka University Venture Capital
  • Taiho Innovations
  • Mitsubishi UFJ Capital
  • QB Capital
  • SBI Investment
Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇯🇵 Japan · Fukuoka HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GAIA BioMedicine on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GAIA BioMedicine on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.